As 5 more biotechs file their IPOs, one Nas­daq of­fi­cial does­n't see mo­men­tum slow­ing down any­time soon

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

It’s been a heck of a ride for the biotech IPO mar­ket over the last year and a half, with 2020 set­ting record fig­ures and 2021 on track to reach even greater heights. And as an­oth­er five bio­phar­mas filed their S-1s late Fri­day, one ex­pert doesn’t see a slow­down oc­cur­ring any time soon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER